In cholangiocarcinoma specifically, focused reviews emphasize CAF dominance and growth-factor handling as druggable stromal functions, situating IGF/IGFBP biology—including IGFBP-6—within tractable paracrine networks that might be leveraged for therapy or biomarker development [39]. This evidence concerns the gene IGF1 and cholangiocarcinoma.